Monitor topline OL data in Q2 2026 and FDA Type B meeting outcome for BLA readiness. The $200.4M cash runway reduces near-term dilution risk.
LRMR drugs
LRMR drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $3.89entry
- T+1 · 6mo ago −7.97%α −6.74% · $3.58
- T+5 · 6mo ago −8.23%α −7.51% · $3.57
- T+20 · 5mo ago −10.80%α −9.94% · $3.47
- T+60 · 3mo ago +3.08%α −0.50% · $4.01
Price Chart
How similar events traded
Executive Summary
Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company advanced its BLA for nomlabofusp toward accelerated approval, planning a rolling submission starting June 2026 with topline open-label data expected Q2 2026.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.31 vs consensus -$0.57 (45.6% beat)
- Net loss $29.6M vs $29.3M YoY; R&D expenses $25.0M down from $26.6M
- Cash, cash equivalents and marketable securities $200.4M as of March 31, 2026
- Planning rolling BLA submission for nomlabofusp starting June 2026; topline OL data expected Q2 2026
- Breakthrough Therapy Designation granted by FDA in February 2026
- $115M public offering completed in February 2026, net proceeds $107.6M
- Projected cash runway into Q2 2027
Financial Impact
EPS beat of 45.6% vs consensus; cash position $200.4M; net loss $29.6M
Risk Factors
- BLA submission and FDA approval are uncertain; regulatory delays or negative feedback could reverse gains
- No revenue; pre-commercial stage with high cash burn ($29.6M/quarter)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294760 |
Track record
13 reports on LRMR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
- Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
- Nov 12, 20264d ago Insider Cluster Bullish 4/10 Entry $3.02 Now $3.00 −0.66% settles Feb 11
- Nov 9, 20267d ago 8-K Bullish 7/10 Entry $2.69 Now $3.00 +11.52% settles Feb 8
- Nov 5, 202611d ago Press Release Neutral 2/10 Entry $2.39 Now $3.00 +25.52% settles Feb 4
- Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
- May 14, 202626w ago 8-K Bullish 7/10 No price data
- May 14, 202626w ago Press Release Bullish 7/10 Viewing Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
- Mar 19, 202634w ago Press Release Mixed 7/10 Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers